-
1 Comment
Shanghai Shen Lian Biomedical Corporation is currently in a long term downtrend where the price is trading 10.2% below its 200 day moving average.
From a valuation standpoint, the stock is 67.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 16.1.
Shanghai Shen Lian Biomedical Corporation's total revenue rose by 425.7% to $148M since the same quarter in the previous year.
Its net income has increased by 9191.0% to $77M since the same quarter in the previous year.
Finally, its free cash flow fell by 125.3% to $-3M since the same quarter in the previous year.
Based on the above factors, Shanghai Shen Lian Biomedical Corporation gets an overall score of 2/5.
| ISIN | CNE100003P17 |
|---|---|
| CurrencyCode | CNY |
| Exchange | SHG |
| Industry | Biotechnology |
| Sector | Healthcare |
| Market Cap | 3B |
|---|---|
| Beta | 0.68 |
| Target Price | None |
| PE Ratio | 35.3 |
| Dividend Yield | 1.0% |
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688098.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
